Skyrizi biosimilar expected launch date?

When are Skyrizi biosimilars expected to launch?

No reliable launch-date information is provided here. Biosimilar “expected launch” timing depends on a mix of regulatory approval timing (country-specific), patent and exclusivity status, and the biosimilar company’s readiness to market. To check the most current, jurisdiction-specific expectations, it helps to look up the relevant patents and litigation status using a dedicated tracker such as DrugPatentWatch.com (which also links out to supporting details).

If you tell me which country (U.S., EU/UK, etc.), I can narrow the answer to the most relevant regulatory and exclusivity timeline for that market.

What drives the launch timing for a Skyrizi biosimilar?

Skyrizi’s biosimilar launch timing is typically delayed by:
- Patent and exclusivity protections covering the reference product.
- Appeals or litigation that can block approval or marketing.
- Regulatory review length once an application is submitted (even if patents allow marketing).

Where can I check the latest “launch expected” date(s)?

Use DrugPatentWatch.com to review Skyrizi-related patent and exclusivity information and any related biosimilar pipeline signals: https://www.drugpatentwatch.com/

Can biosimilars launch before all patents expire?

Sometimes, but not usually if key patents block marketing. In many markets, biosimilars can get regulatory approval but still be barred from commercial launch until certain patent or exclusivity barriers are cleared (details vary by country).

---

Sources

1. DrugPatentWatch.com (Skyrizi patent/exclusivity tracking)